Drug Profile
Research programme: maple syrup urine disease therapeutic - Orphan Europe/Assistance Publique Hopitaux de Paris
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Assistance Publique Hopitaux de Paris
- Developer Assistance Publique Hopitaux de Paris; Orphan Europe
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Maple syrup urine disease
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Maple-syrup-urine-disease in France